INDICATION(S)
Concomitant temozolomide and radiation followed by maintenance temozolomide is recommended for adjuvant treatment of newly diagnosed glioblastoma multiforme (GBM). 1 Bevacizumab is recommended in recurrent disease, as monotherapy or in combination with temozolomide. 1 The studies reviewed utilized bevacizumab and temozolomide plus radiation as initial therapy in patients with newly diagnosed GBM. [2] [3] [4] [5] [6] [7] 
DRUG PREPARATION
Follow institutional policies for preparation of hazardous medications when preparing bevacizumab and dispensing temozolomide. 2. Temozolomide should be taken on an empty stomach, with a glass of water to minimize the incidence of nausea. Food may increase the incidence of gastric irritation and can influence drug absorption unpredictably. 8 Note: Gy = gray; IV = intravenous; PO = oral. 2. Option to extend treatment to total of 12 cycles. 2 3. Temozolomide 150 mg/m 2 PO days 1 thru 7, every 28 days for 6 cycles. Bevacizumab administered on days 8 and 22 of each cycle. 4 4. Option to extend treatment beyond original 6 cycles left to physician discretion. 6 5. Started maintenance phase 2 weeks after completion of adjuvant/concomitant phase for maximum of 24 cycles. 6 Cancer Chemotherapy Update consists of multiple capsule strengths. It may be more pragmatic to dispense each day's combination of capsules in separate containers to limit the potential for patients to erroneously combine capsules in the wrong dose.
SUPPORTIVE CARE
A. Acute and Delayed Emesis Prophylaxis: The risk of emesis for this regimen differs between the concomitant phase and the maintenance phase. The emetogenic risk for each phase will be discussed separately.
The risk of emesis in the concomitant phase is predicted to be less than 10%. 10 For most patients, prophylactic antiemetic therapy is not required. [11] [12] [13] The studies reviewed reported grade 3 or greater nausea or vomiting in only 2% to 5% of patients. 2, 4, 5 The risk of radiationinduced nausea and vomiting with this regimen is considered low and may warrant prophylaxis or rescue. 11, 12 If a patient develops nausea or vomiting requiring antiemetic therapy, prophylactic therapy is recommended for the balance of radiation treatments. 11 One of the following regimens is recommended: 1. Ondansetron 8 mg to 16 mg given PO 30 minutes before radiation. 2. Granisetron 1 mg to 2 mg given PO 30 minutes before radiation. 3. Dolasetron 100 mg given PO 30 minutes before radiation. Patients who experience significant nausea or vomiting with one of these regimens should receive an agent from a different pharmacologic category. 10, 11, 13 A few small studies suggest substituting granisetron for ondansetron in subsequent treatment cycles; however none of these reports found the improvement to be statistically significant. [14] [15] [16] [17] [18] Dexamethasone, 4 mg to 24 mg per day, is commonly used for patients with diseaserelated cerebral edema. [19] [20] [21] While these doses may also provide antiemetic benefit, additional dexamethasone is likely unnecessary.
The maintenance phase of this regimen utilizes a higher dose of temozolomide and is predicted to cause nausea in 30% to 90% of patients. 10, 12 In one of the studies reviewed, where use of a 5-hydroxytryptamine receptor antagonist was stro ngly recommended, grade 3 nausea or vomiting was reported in the maintenance phase in 5% of patients. 2 Other studies reviewed failed either to report any nausea or vomiting or to distinguish between the concomitant and maintenance phases. [3] [4] [5] [6] [7] Prophylactic antiemetic therapy with a serotonin antagonist is recommended prior to each temozolomide dose during the maintenance phase. 10, 12, 13 One of the following regimens may be given 30 minutes prior to therapy: 1. Ondansetron 16 mg to 24 mg PO given once daily before temozolomide. 2. Granisetron 1 mg to 2 mg PO given once daily before temozolomide. 3. Dolasetron 100 mg PO given once daily before temozolomide.
B. Breakthrough Nausea and Vomiting 10,11,13 :
Patients should receive a prescription for an antiemetic to treat breakthrough nausea. One of the following regimens is suggested: A few small studies suggest that higher doses of granisetron (3 mg IV or 40 mcg/kg to 240 mcg/ kg) [14] [15] [16] [17] [18] may be effective in treating breakthrough nausea; however none of these reports found the improvement to be statistically significant. C. Hematopoietic Growth Factors: Accepted practice guidelines and pharmaco economic analysis suggest that an antineoplastic regimen have a greater than 20% incidence of febrile neutropenia before prophylactic use of colony stimulating factors (CSFs) is warranted. For regimens with an incidence of febrile neutropenia between 10% and 20%, use of CSFs should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of CSFs is not recommended. 22, 23 None of the trials reviewed reported febrile neutropenia. [2] [3] [4] [5] 7 Severe (grade 3 or 4) neutropenia was reported in 7% to 33% of patients in the bevacizumab and temozolomide trials reviewed. 2, 5 While likely in the maintenance period, no distinction was made as to what phase of treatment the patient experienced the neutropenia. Prophylactic use of CSFs is not recommended. [2] [3] [4] [5] 7 CSFs may be considered if a patient experiences febrile or grade 4 neutropenia in a prior cycle of bevacizumab and temozolomide. D. Pulmonary: Prophylaxis against Pneumocystis jirovecii or Pneumocystis carinii (PCP) is advised for all patients receiving concomitant temozolomide and radiotherapy and should be continued until recovery from lymphocytopenia. 24 In the studies reviewed, Gilbert et al 2 utilized pneumocystis prophylaxis in patients with CD4 counts less than 200 per cubic millimeter; Ney et al 5 did not require prophylaxis, but instead left it to the discretion of the treating physician; and Omuro et al 6 recommended prophylaxis for all patients.
MAJOR TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:// evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities, but make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. 
A. Cardiovascular

